1617501-33-3

Basic information

• Product Name: methyl 3-(((trans)-4-((tert-butoxycarbonyl)amino)cyclohexyl)oxy)-5-chloro-2-methylbenzoate
• Synonyms: methyl 3-(((trans)-4-((tert-butoxycarbonyl)amino)cyclohexyl)oxy)-5-chloro-2-methylbenzoate
• CAS NO: 1617501-33-3
• Molecular Weight: 397.899
• Mol File: 1617501-33-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl 3-(((trans)-4-((tert-butoxycarbonyl)amino)cyclohexyl)oxy)-5-chloro-2-methylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-(((trans)-4-((tert-butoxycarbonyl)amino)cyclohexyl)oxy)-5-chloro-2-methylbenzoate(1617501-33-3)
• EPA Substance Registry System: methyl 3-(((trans)-4-((tert-butoxycarbonyl)amino)cyclohexyl)oxy)-5-chloro-2-methylbenzoate(1617501-33-3)

Safety Data

• Hazardous Substances Data: 1617501-33-3(Hazardous Substances Data)

Upstream product

• 1549275-48-0 5-chloro-3-iodo-2-methylbenzoic acid 
• 1007306-61-7 (1S,4S)-4-((tert-butoxycarbonyl)amino)-cyclohexyl methanesulfonate 
• 7499-06-1 5-chloro-2-methylbenzoic acid 
• 167081-25-6 cis-(4-hydroxycyclohexyl)carbamic acid tert-butyl ester 

Downstream Products

• 1617501-32-2 3-(((1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)oxy)-5-chloro-2-methylbenzoic acid 
• 1617501-06-0 tert-butyl ((1r,4r)-4-(5-chloro-3-(((2,6-dimethyl-4-oxo-1,4-dihydropyridin-3-yl)methyl)carbamoyl)-2-methylphenoxy)cyclohexyl)carbamate 
• 1617501-38-8 methyl 5-chloro-3-(((1r,4r)-4-(dimethylamino)cyclohexyl)oxy)-2-methylbenzoate 
• 1617501-39-9 5-chloro-3-(((1r,4r)-4-(dimethylamino)cyclohexyl)oxy)-2-methylbenzoic acid 

Relevant articles and documents

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. Epigenetic modifications play an important role in the regulation of many cellular processes including cell proliferation, differentiation, and cell survival. Global epigenetic modifications are common in cancer, and include global changes in DNA and/or histone methylation, dysregulation of non-coding RNAs and nucleosome remodeling leading to aberrant activation or inactivation of oncogenes, tumor suppressors and signaling pathways.